leisure time -WSS

leisure time

author：entertainment 2025-09-06 03:54:57 - browse：79

Two boxes of Ozempic stack on each other, while one lean on the stack tilted — health coverage from STAT — SEBASTIEN BOZON/AFP via Getty Images

Novo Nordisk’s Ozempic cut the risk of death in a trial of patients with type 2 diabetes and chronic kidney disease, suggesting it may offer some added benefits over other classes of drugs approved to treat this population.

Specifically, the diabetes drug cut the risk of cardiovascular-related deaths by 29% and all-cause deaths by 20%. Given the study parameters, this implies that over three years, 39 people would need to be treated to prevent one death from any cause, according to new results presented Friday at a meeting of the European Renal Association and published in the New England Journal of Medicine.

Ozempic also lowered the risk of major heart complications — including cardiovascular-related death, heart attack, or stroke — by 18%, driven primarily by the reduced rate of heart-linked death.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： NIH launches clinical trials and new research office for long Covid

hotspot

WSS

Did you have Obamacare on your GOP debate bingo card?

Data show record exodus of life scientists from academia

Sudafed saga points to U.S. issues with evaluating older drugs

Mega Millions pot grows to $1.25 billion after no winner

Mitch McConnell episode has important public health takeaway

New safety details link Apellis eye drug to rare cases of blindness

entertainment

leisure time

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

hotspot

Wildfire smoke exposes gaps in outdoor worker protections

STAT Virtual Event: How to Increase Diversity in Clinical Trials

Jerome Adams on the need for new antivirals for Covid

National panel will explore requiring free Covid tests

Alkermes shareholders re

EQRx, failed developer of low

Dobbs anniversary: the lost opportunity of abortion as health care

Kaiser Permanente unions announce official strike date

After affirmative action ruling, medical educators look to 'holistic review'

How one patient went off dialysis — and others can too

hotspot

Why do women spend more than men on medical expenses?

Data show record exodus of life scientists from academia

Mega Millions pot grows to $1.25 billion after no winner

Lawsuit alleges UnitedHealth Group unit illegally denied claims

Health tech startups drop sharply from 2021 highs

How one patient went off dialysis — and others can too

explore

explore

hotspot

explore